EUCTR2012-003292-19-ES进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter, 24 week study assessing the safety and efficacy of lixisenatide in older patients with type 2 diabetes inadequately controlled on their current diabetes treatment regimen - GetGoal-O
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Older patients, aged 70 years and above, with T2DM inadequately controlled on their current anti-diabetic regimen
- •? Signed written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 340
排除标准
- •? At screening HbA1c ?7.0% or >10% (Acknowledging that the threshold of 7% may not be appropriate for all older patients and that this is the responsibility of the investigator to include the patient based on an individual evaluation of the expected benefits of better glycemic control versus risk of hypoglycemia)
- •? At screening patients on both basal insulin and sulfonylurea or basal insulin and meglitinides
- •? At screening FPG >250 mg/dL (>13.9 mmol/L)
- •? Type 1 diabetes mellitus or history of ketoacidosis within one year prior to the screening visit.
- •? Type 2 diabetes mellitus diagnosed less than 1 year prior to screening
- •? Anti-diabetic treatment not at a stable regimen or initiated within the last 3 months prior to screening
- •? Treatment within the 3 months preceding the screening with other antidiabetic agent than allowed background therapy. Allowed therapy includes metformin, sulfonylurea [except glibenclamide >10mg, glicazide >160mg], meglitinides [except repaglinide >6mg], pioglitazone and basal insulin and should follow local product circulars and labeling restrictions for the study population. .
- •? Patients who have been on an approved or an investigational GLP-1 medication (exenatide, liraglutide, lixisenatide or others)
- •? History of severe hypoglycemia associated with symptoms unawareness or results in unconsciousness/coma/seizure in the 6 months prior to screening
- •? BMI <22 or >40 kg/m²
- •? Malnutrition assessed clinically by the investigator or any sub-investigator and by MNA-SF score <12 in countries (the judgment of the investigator prevails on questionnaires scores)
- •? Cognitive disorder and dementia assessed clinically by the investigator or any sub investigator and by MMSE score <24 (the judgment of the investigator prevails on questionnaires scores), or any neurologic disorder that will affect the patient?s ability to participate in the study
- •? Patient who have an eGFR (using the Modification of Diet in Renal Disease {MDRD} formula <30ml/min/1.73m2
- •? Patients with severe or uncontrolled disease, or any clinically significant abnormality identified on physical examination or investigational clinical procedure that, in the judgment of the investigator or any sub-investigator, would preclude safe completion of the study or constrains efficacy assessment
- •? Laboratory findings at the time of screening:
- •- Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range
- •- ALT or AST >3 times ULN
- •- Calcitonin >20 pg/mL (5.9 pmol/L)
- •? Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (ie, worsening) and not controlled (ie, prolonged nausea and vomiting) gastroesophageal reflux disease within 6 months prior to screening
- •? History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease
- •? Personal or immediate family history of medullary thyroid cancer or genetic conditions that predisposes to medullary thyroid cancer (eg, multiple endocrine neoplasia syndromes)
研究者
相似试验
进行中（未招募）
不适用
Efficacy and safety of lixisenatide versus placebo on top of basal insulin and/or oral antidiabetic treatment in older type 2 diabetic patientsEUCTR2012-003292-19-DESanofi-Aventis Recherche & Développement340
进行中（未招募）
不适用
Efficacy and safety of lixisenatide versus placebo on top of basal insulin and/or oral antidiabetic treatment in older type 2 diabetic patientsType 2 Diabetes mellitusMedDRA version: 17.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-003292-19-SESanofi-Aventis Recherche & Développement340
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with Type 2 diabetes insufficiently controlled with basal insulin. - GETGOALEUCTR2007-005886-36-FRSanofi -Aventis Recherche & Développement450
已完成
2 期
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CTRI/2010/091/000285ovartis Healthcare Private Limited360
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with Type 2 diabetes insufficiently controlled with basal insulin. - GETGOALType II DiabetesMedDRA version: 10.1Level: LLTClassification code 10067585Term: <Manually entered code. Term in E.1.1>EUCTR2007-005886-36-GBSanofi -Aventis Recherche & Développement450